Physician profile
Eli Schneck
NPI 1194384743
$1,486.94
in general payments reported to CMS, 2019-2025
12 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $125 · 2024: $428 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.77 | 2024-2025 | |
| Lundbeck LLC | $379.91 | 2024-2025 | Vyepti |
| Pfizer INC. | $321.97 | 2022-2025 | |
| Dexcom, INC. | $91.81 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $27.63 | 2022 | |
| W. L. Gore & Associates, INC. | $25.62 | 2024 | Gore Cardioform Septal Occluder |
| E.R. Squibb & Sons, L.L.C. | $24.79 | 2024 | Camzyos |
| Sun Pharmaceutical Industries INC. | $23.53 | 2023 | Ilumya |
| Amarin Pharma, INC. | $19.68 | 2022 | |
| Medtronic, INC. | $19.50 | 2022 | |
| Csl Behring | $17.23 | 2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Schneck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.